Peter Enzinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peter Enzinger has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Joshua Remland
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
32 shared publications - Lauren K. Brais
Dana-Farber Cancer Institute, Boston, MA
32 shared publications - Andressa Dias Costa
Dana-Farber Cancer Institute 1 Department of Medical Oncology Harvard Medical School, Boston, Massachusetts
31 shared publications - Benjamin L. Schlechter
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
31 shared publications - Brandon M. Huffman
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
31 shared publications - Brian M. Wolpin
Dana-Farber Cancer Institute, Boston, MA
31 shared publications
Latest Publications
- 21 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Ultrasensitive circulating tumor DNA analysis improves detection of molecular residual disease in locally advanced esophageal cancer
Purpose: Circulating tumor DNA (ctDNA) could be a powerful prognostic biomarker for patients with locally advanced esophageal cancer but higher sensitivity is needed. An ultrasensitive test could enable improved treatment decision-making by accurately identifying patients with residual disease. Experimental Design: 331 plasma samples from 36 patients were collected both preoperatively and postoperatively. We applied MAESTRO-Pool (Minor Allele Enriched Sequencing Through Recognition Oligonucleotides) of the Broad Institute and the Oncodetect® V2 test of Exact Sciences, two MAESTRO-based, ultrasensitive, tumor-informed, mutation enrichment sequencing tests, to all samples. Results: With the Oncodetect V2 test, we found 9 of 14 patients (64%) with recurrence and postoperative plasma available tested ctDNA-positive at their first postoperative sample and all 14 patients tested ctDNA-positive for at least one postoperative sample prior to recurrence. ctDNA was detected below the limit of detection for first-generation assays in 59% of all samples in which we detected ctDNA. By tracking a median of 2.1-fold more mutations per patient (up to 5,000 total mutations per patient), the Oncodetect V2 test showed highly concordant results (98.9% positive percent agreement), improved ctDNA detection, and longer lead times to recurrence as compared to MAESTRO-Pool. Conclusion: ctDNA detection after curative-intent therapy for locally advanced esophageal cancer had strong positive and negative predictive values for recurrence. Given the low ctDNA levels observed, and that all patients with recurrence were eventually ctDNA-positive, ctDNA testing in esophageal cancer may benefit from ultrasensitive tests that detect part-per-million levels of ctDNA.
- 21 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Ultrasensitive circulating tumor DNA analysis improves detection of molecular residual disease in locally advanced esophageal cancer
Purpose: Circulating tumor DNA (ctDNA) could be a powerful prognostic biomarker for patients with locally advanced esophageal cancer but higher sensitivity is needed. An ultrasensitive test could enable improved treatment decision-making by accurately identifying patients with residual disease. Experimental Design: 331 plasma samples from 36 patients were collected both preoperatively and postoperatively. We applied MAESTRO-Pool (Minor Allele Enriched Sequencing Through Recognition Oligonucleotides) of the Broad Institute and the Oncodetect® V2 test of Exact Sciences, two MAESTRO-based, ultrasensitive, tumor-informed, mutation enrichment sequencing tests, to all samples. Results: With the Oncodetect V2 test, we found 9 of 14 patients (64%) with recurrence and postoperative plasma available tested ctDNA-positive at their first postoperative sample and all 14 patients tested ctDNA-positive for at least one postoperative sample prior to recurrence. ctDNA was detected below the limit of detection for first-generation assays in 59% of all samples in which we detected ctDNA. By tracking a median of 2.1-fold more mutations per patient (up to 5,000 total mutations per patient), the Oncodetect V2 test showed highly concordant results (98.9% positive percent agreement), improved ctDNA detection, and longer lead times to recurrence as compared to MAESTRO-Pool. Conclusion: ctDNA detection after curative-intent therapy for locally advanced esophageal cancer had strong positive and negative predictive values for recurrence. Given the low ctDNA levels observed, and that all patients with recurrence were eventually ctDNA-positive, ctDNA testing in esophageal cancer may benefit from ultrasensitive tests that detect part-per-million levels of ctDNA.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 3: Presence of canakinumab does not interfere with the ability to detect IL-1b in patient serum. Baseline serum from three randomly selected patients with pancreatic ductal adenocarcinoma was evaluated by cytokine bead array for IL-1b. For each patient sample, canakinumab was spiked in at the indicated concentrations. Note that measured IL-1b values were consistent across all samples from the same patient, regardless of the presence of canakinumab.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 3: Presence of canakinumab does not interfere with the ability to detect IL-1b in patient serum. Baseline serum from three randomly selected patients with pancreatic ductal adenocarcinoma was evaluated by cytokine bead array for IL-1b. For each patient sample, canakinumab was spiked in at the indicated concentrations. Note that measured IL-1b values were consistent across all samples from the same patient, regardless of the presence of canakinumab.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 6. Cell populations identified by transcriptional profiling from tumor biopsies. (A) UMAP of all cells in the dataset, colored by cluster. (B-C) Relative expression of representative genes of the six major compartments across the full dataset. (D) Relative expression of IL1B, IL1R1, PDCD1, PDCDLG1, and PDCDLG2 across the full dataset. (E) The percent of each myeloid cluster that is found in each of the samples, separated into baseline and treated subgroups (Wilcoxon rank-sum test).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 6. Cell populations identified by transcriptional profiling from tumor biopsies. (A) UMAP of all cells in the dataset, colored by cluster. (B-C) Relative expression of representative genes of the six major compartments across the full dataset. (D) Relative expression of IL1B, IL1R1, PDCD1, PDCDLG1, and PDCDLG2 across the full dataset. (E) The percent of each myeloid cluster that is found in each of the samples, separated into baseline and treated subgroups (Wilcoxon rank-sum test).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 7: Macrophage subtypes are unaffected by treatment in patients in SR-1. (A) Baseline and on-treatment biopsies from patients (n = 6 paired samples) in the SR-1 trial were analyzed by multiplex immunofluorescence using the indicated antibodies. Representative image of the macrophage panel is shown. (B) Densities of total macrophages (CD68+ or CD163+ cells). (C) Densities of M1 polarized macrophages (CD86+IRF5+). (D) Densities of M2 polarized macrophages (CD206+CD163+).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 7: Macrophage subtypes are unaffected by treatment in patients in SR-1. (A) Baseline and on-treatment biopsies from patients (n = 6 paired samples) in the SR-1 trial were analyzed by multiplex immunofluorescence using the indicated antibodies. Representative image of the macrophage panel is shown. (B) Densities of total macrophages (CD68+ or CD163+ cells). (C) Densities of M1 polarized macrophages (CD86+IRF5+). (D) Densities of M2 polarized macrophages (CD206+CD163+).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 2: Pharmacokinetics of canakinumab. Serum levels of canakinumab were measured in patients on SR-1 at the indicated time points.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 2: Pharmacokinetics of canakinumab. Serum levels of canakinumab were measured in patients on SR-1 at the indicated time points.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 1: Progression-free survival for SR-1, an open-label multicenter phase Ib study evaluating gemcitabine, n(ab)-paclitaxel, canakinumab and spartalizumab in advanced pancreatic ductal adenocarcinoma. A) PFS for the 10 patients in SR-1 is shown. B) OS for the 10 patients in SR-1 is shown. C) PFS for the 11 patients in the GnP cohort is shown.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 1: Progression-free survival for SR-1, an open-label multicenter phase Ib study evaluating gemcitabine, n(ab)-paclitaxel, canakinumab and spartalizumab in advanced pancreatic ductal adenocarcinoma. A) PFS for the 10 patients in SR-1 is shown. B) OS for the 10 patients in SR-1 is shown. C) PFS for the 11 patients in the GnP cohort is shown.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 2: Patient sample information and types of experimental data collected from each patient.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 2: Patient sample information and types of experimental data collected from each patient.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 3: Serum samples from baseline and on-treatment time points from patients in SR-1, the standard of care cohort, and healthy people who donated blood 28 days apart were analyzed by cytokine bead array. Significance was determined by Wilcoxon matched-pairs signed rank test.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 3: Serum samples from baseline and on-treatment time points from patients in SR-1, the standard of care cohort, and healthy people who donated blood 28 days apart were analyzed by cytokine bead array. Significance was determined by Wilcoxon matched-pairs signed rank test.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 1: Selected Adverse Events reported in ≥5 subjects (any grade) or ≥3 subjects for Grade 3 from patients in SR-1. Select immune-related adverse events are also shown.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 1: Selected Adverse Events reported in ≥5 subjects (any grade) or ≥3 subjects for Grade 3 from patients in SR-1. Select immune-related adverse events are also shown.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 5: Addition of TNFa ameliorates myeloid suppression in vitro. (A) Histogram of HLA-DR mean fluorescence intensity of CD33+ SSCA high cells from monocytes cocultured for a week with 75 pg/ML M-CSF with the addition of 10 ng/mL each GM-CSF/ IL-6 or 10ng/mL IL-1b with or without an IL-1b blocking antibody. (B) Induced MoMDSCs from panel A were then cultured with CFSE-labeled T cells for 3 days coculture at a 1:1 ratio, and T cell proliferation was assessed by flow cytometry. Proliferation indices were calculated. (C) MoMDSCs induced from monocytes cultured for 7 days with the indicated cytokines were then cultured with CFSE-labeled T cells for 3 days coculture at a 1:1 ratio, and T cell proliferation was assessed by flow cytometry. Representative histograms are shown. (D) Proliferation indices from the data shown in C were calculated.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 5: Addition of TNFa ameliorates myeloid suppression in vitro. (A) Histogram of HLA-DR mean fluorescence intensity of CD33+ SSCA high cells from monocytes cocultured for a week with 75 pg/ML M-CSF with the addition of 10 ng/mL each GM-CSF/ IL-6 or 10ng/mL IL-1b with or without an IL-1b blocking antibody. (B) Induced MoMDSCs from panel A were then cultured with CFSE-labeled T cells for 3 days coculture at a 1:1 ratio, and T cell proliferation was assessed by flow cytometry. Proliferation indices were calculated. (C) MoMDSCs induced from monocytes cultured for 7 days with the indicated cytokines were then cultured with CFSE-labeled T cells for 3 days coculture at a 1:1 ratio, and T cell proliferation was assessed by flow cytometry. Representative histograms are shown. (D) Proliferation indices from the data shown in C were calculated.